An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Kezar Life Sciences announced the grant of stock options to its newly appointed Chief Business Officer, Nick Mordwinkin, totaling 200,000 shares at an exercise price of $9.35, equal to the stock's closing price on August 1, 2022. An additional employee received 60,000 shares under similar conditions. The options will vest over four years, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4), aimed at incentivizing key personnel. Kezar focuses on treatments for immune-mediated and oncologic disorders, advancing candidates like Zetomipzomib and KZR-261.
Positive
Granting of stock options incentivizes key personnel, potentially enhancing company performance.
Zetomipzomib in Phase 2 for lupus nephritis shows promise in treating chronic immune-mediated diseases.
KZR-261 is undergoing a Phase 1 trial, indicating continued development in oncology.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that, in connection with the previously announced appointment of Nick Mordwinkin, Pharm.D., Ph.D., as the Company’s Chief Business Officer, the Compensation Committee of the company’s Board of Directors granted Dr. Mordwinkin a nonqualified stock option to purchase 200,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar’s common stock on August 1, 2022. In addition, the Compensation Committee of the company’s Board of Directors granted one additional employee a nonqualified stock option to purchase 60,000 shares of its common stock with an exercise price of $9.35 per share, which is equal to the closing price of Kezar’s common stock on August 1, 2022. The stock options were granted as an inducement award material to the individuals entering into employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options will vest over a four-year period, with 25% of each option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date. The options are subject to the terms and conditions of Kezar’s 2022 Inducement Plan and the stock option agreement covering the grants.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.
